A MedTech startup based in the Middle East had a working prototype and promising early
trials but lacked investor-ready documentation. Despite multiple conversations with
European seed funds, investors struggled to understand the business model and scalability
potential.
What We Did
- Conducted an intensive discovery exercise to build a clear market thesis highlighting the commercial viability and regional adoption curve.
- Created a robust financial model with realistic pricing corridors, clinical rollout assumptions, and reimbursement sensitivity analysis.
- Reworked the pitch deck to focus on patient outcomes, recurring revenue potential, and regulatory advantage.
- Designed a curated outreach campaign targeting early-stage investors across Europe, including specialized MedTech funds and family offices.
Outcome
- Within six weeks, the company received 11 investor calls and 2 term sheets.
- Closed a seed round at a 35 percent valuation premium compared to prior offers.
Key Takeaway
Brisk Capital Services transformed technical validation into financial clarity, enabling the founder to bridge regional capital and international confidence.